Candriam S.C.A. Lowers Position in Zai Lab Limited (NASDAQ:ZLAB)

Candriam S.C.A. trimmed its stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 3.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 375,479 shares of the company's stock after selling 14,544 shares during the quarter. Candriam S.C.A. owned 0.34% of Zai Lab worth $9,834,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. US Bancorp DE grew its position in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after buying an additional 5,534 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Zai Lab in the third quarter worth approximately $225,000. Daiwa Securities Group Inc. grew its holdings in Zai Lab by 4,851.8% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company's stock worth $231,000 after acquiring an additional 9,364 shares in the last quarter. RBF Capital LLC purchased a new stake in shares of Zai Lab in the 3rd quarter valued at approximately $241,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Zai Lab by 15.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock valued at $290,000 after purchasing an additional 1,502 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on ZLAB. Scotiabank started coverage on Zai Lab in a report on Friday. They issued a "sector outperform" rating and a $55.00 target price on the stock. Bank of America reaffirmed a "neutral" rating and set a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald raised Zai Lab to a "strong-buy" rating in a research report on Tuesday, March 4th.

Remove Ads

Zai Lab Trading Up 1.9 %

NASDAQ:ZLAB traded up $0.66 during midday trading on Tuesday, hitting $35.35. 429,558 shares of the company were exchanged, compared to its average volume of 750,021. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $37.99. The company has a market capitalization of $3.87 billion, a PE ratio of -12.76 and a beta of 1.08. The company has a fifty day simple moving average of $28.62 and a 200 day simple moving average of $26.70.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. As a group, equities research analysts expect that Zai Lab Limited will post -2.58 EPS for the current year.

Insider Activity

In related news, insider Rafael Amado sold 7,583 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the transaction, the insider now owns 33,834 shares in the company, valued at $889,157.52. The trade was a 18.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00. Following the sale, the chief executive officer now directly owns 494,117 shares of the company's stock, valued at $17,032,212.99. The trade was a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 122,127 shares of company stock valued at $4,024,442. 13.88% of the stock is currently owned by company insiders.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.